Bay­er takes SGLT2 hope­fuls head on with FDA ap­proval for new kid­ney dis­ease drug

The FDA on Fri­day ap­proved Bay­er Phar­ma­ceu­ti­cals’ chron­ic kid­ney dis­ease drug Keren­dia (finerenone), the first and on­ly non­s­teroidal min­er­alo­cor­ti­coid re­cep­tor an­tag­o­nist, of­fer­ing a new op­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER